| |
| |
|
| Insider
Information: |
Booth Bruce |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
4,638,028 |
|
|
Indirect Shares
|
24,470,653 |
|
|
| Direct
Value |
$5,333,732 |
|
|
|
Indirect Value
|
$98,107,698 |
|
|
| Total
Shares |
29,108,681 |
|
|
| Total
Value |
$103,441,430 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 80.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Larimar Therapeutics Inc |
LRMR |
Director, 10% Owner |
2016-01-25 |
4,638,028 |
2014-06-24 |
5,632,730 |
Premium* |
|
|
Viridian Therapeutics Ors Shs |
VRDN |
Director |
|
0 |
2018-02-13 |
4,493,670 |
Premium* |
|
|
Cogent Biosciences, Inc. |
COGT |
Director |
2018-04-03 |
0 |
2018-04-03 |
3,361,535 |
Premium* |
|
|
Dianthus Therapeutics Ord Shs |
DNTH |
Director |
2018-06-25 |
0 |
2020-06-29 |
5,367,125 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
|
|
0 |
2024-03-15 |
806,697 |
Premium* |
|
|
Vigil Neuroscience, Inc. |
VIGL |
Director |
2022-01-11 |
0 |
2022-01-11 |
4,808,896 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-15 |
4 |
AS |
$39.31 |
$2,903,336 |
I/I |
(71,764) |
806,697 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-14 |
4 |
AS |
$39.73 |
$2,229,927 |
I/I |
(55,779) |
819,151 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-13 |
4 |
AS |
$42.19 |
$5,880,415 |
I/I |
(139,255) |
828,830 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-12 |
4 |
AS |
$41.94 |
$6,838,813 |
I/I |
(162,918) |
852,995 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
|
– • – |
2024-03-11 |
4 |
AS |
$42.77 |
$2,193,148 |
I/I |
(51,184) |
881,266 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2023-01-12 |
4 |
AS |
$30.29 |
$2,990,229 |
I/I |
(98,720) |
890,148 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2023-01-11 |
4 |
AS |
$29.96 |
$831,510 |
I/I |
(27,754) |
911,740 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-12-15 |
4 |
AS |
$30.00 |
$98,340 |
I/I |
(3,278) |
917,811 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-12-14 |
4 |
AS |
$30.28 |
$11,887,614 |
I/I |
(378,966) |
918,528 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-11-03 |
4 |
AS |
$30.00 |
$2,891,910 |
I/I |
(96,397) |
1,001,417 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-11-02 |
4 |
AS |
$30.02 |
$3,711,042 |
I/I |
(123,619) |
1,022,502 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-11-01 |
4 |
AS |
$30.57 |
$2,357,240 |
I/I |
(77,030) |
1,049,540 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-10-31 |
4 |
AS |
$30.23 |
$3,646,403 |
I/I |
(120,622) |
1,066,388 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2022-10-28 |
4 |
AS |
$30.00 |
$2,731,500 |
I/I |
(91,050) |
1,092,771 |
0 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-01-11 |
4 |
B |
$14.00 |
$7,490,000 |
I/I |
535,000 |
4,808,896 |
2.1 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,859,498 |
1,027,978 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2021-08-11 |
4 |
S |
$61.00 |
$14,770,113 |
I/I |
(242,133) |
0 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2021-03-12 |
4 |
S |
$56.50 |
$12,958,275 |
I/I |
(229,350) |
0 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2020-08-25 |
4 |
A |
$0.00 |
$0 |
I/I |
8,309,270 |
1,112,686 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
Director |
– • – |
2020-08-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
752,398 |
|
- |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2020-06-29 |
4 |
B |
$8.00 |
$10,000,000 |
I/I |
1,250,000 |
1,250,000 |
2.1 |
% |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2019-03-20 |
4 |
S |
$17.86 |
$254,416 |
I/I |
(14,245) |
0 |
0 |
- |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2019-03-20 |
4 |
A |
$0.00 |
$0 |
I/I |
14,245 |
14,245 |
0 |
- |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2019-03-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(726,500) |
4,117,125 |
0 |
- |
|
| DNTH |
Dianthus Therapeutics Ord... |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
4,746,876 |
4,843,625 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
